title: HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation.
abstract: OBJECTIVE
  To evaluate feasibility, safety, and efficacy of peripheral blood stem cell collection (PBSCC) and autologous stem cell transplantation (ASCT), to treat patients diagnosed of high-risk or relapsed HIV-associated lymphoma (HIV+ Ly), responding to highly active antiretroviral therapy (HAART).
  
  
  METHODS
  Prospective and multicentric study in patients with high-risk or relapsed chemosensitive HIV+ Ly, candidate for consolidation with ASCT. Eligibility criteria were similar to those of HIV- lymphoma. HAART was aimed to be maintained during the procedure.
  
  
  RESULTS
  Fourteen patients were admitted. Adequate PBSCC was obtained from all patients (median CD34+ cells was 4.7 x 10(6)/kg). Three patients died before ASCT; two had disease progression and one died from VHC-liver failure. Eleven transplanted patients showed neutrophil engraftment after a median time of 16 days (range, 9-33 days), and nine patients showed platelet engraftment after a median time of 20 days (range, 11-36 days). CD4+ cell counts and HIV viral load (VL) were appropriately preserved along the procedure. No patients died from treatment-related complications. One patient died from lymphoma progression (day +19), and another died in complete remission (CR) with undetectable VL, 15 months after transplant, due to infection. One patient relapsed at 32 months after ASCT. The remaining eight patients are alive in CR with an event-free survival of 65% and a median follow-up of 30 months after ASCT (range, 7-36 months).
  
  
  CONCLUSIONS
  These results show that feasibility, safety, and efficacy of PBSCC and ASCT in HIV+ Ly patients responding to HAART are similar to those observed in the HIV- lymphoma setting.
authors.affiliation: Bone Marrow Transplantation Unit and Haematology Department, Hospital G. U. Gregorio Marañón, Madrid, Spain.
authors.forename: David
authors.initials: D
authors.lastname: Serrano
authors.forename: Rafael
authors.initials: R
authors.lastname: Carrión
authors.forename: Pascual
authors.initials: P
authors.lastname: Balsalobre
authors.forename: Pilar
authors.initials: P
authors.lastname: Miralles
authors.forename: Juan
authors.initials: J
authors.lastname: Berenguer
authors.forename: Ismael
authors.initials: I
authors.lastname: Buño
authors.forename: Alfonso
authors.initials: A
authors.lastname: Gómez-Pineda
authors.forename: José M
authors.initials: JM
authors.lastname: Ribera
authors.forename: Eulogio
authors.initials: E
authors.lastname: Conde
authors.forename: José L
authors.initials: JL
authors.lastname: Díez-Martín
mesh_terms: D000328:Adult; D018952:Antigens, CD34; D023241:Antiretroviral Therapy, Highly Active; D006085:Graft Survival; D006801:Humans; D008137:Longitudinal Studies; D016483:Lymphoma, AIDS-Related / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D012074:Remission Induction; D016019:Survival Analysis; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D018952:Antigens, CD34